1. sunbet(中国)

      Efficacy and safety of statins and ezetimibe in primary prevention of cardiovascular disease in the elderly: A systematic review protocol.

      Fernandez-Gonzalez J, Irigoyen-Rodriguez I, Alzueta-Isturiz N, Echeverría-Gorriti A, Lozano C, Garjon-Parra J

      Published: 2023-04-19 DOI: 10.17504/protocols.io.eq2ly7y7elx9/v1
      AI 解读
      浏览 1306

      Abstract

      Cardiovascular diseases (CVD) are the leading cause of death globally (1). The risk increases with age. Statins and ezetimibe are indicated for the prevention of CVD and its efficacy in secondary prevention (patients who have had an adverse CVD event) has been demonstrated in all age groups (2). However, there is controversy about its use in primary prevention (people without established CVD) in the elderly (3, 4), since the patients older than 75 years are a group of underrepresented population in clinical trials. This age threshold has been used in meta-analysis of randomized controlled trials that did not shown evidence of an effect in cardiovascular events in people older than 75 years without vascular disease (5–7) . The latest clinical guidelines published in the United States and Europe differ notably in their recommendations (8–10).

      As other medicines, statins and ezetimibe are not exempt from adverse events. These are more frequent in geriatric patients, since comorbidities and polypharmacy frequently coexist. These factors can increase the risk of drug interactions and contribute to the impairment of renal and hepatic function (11).

      We describe a protocol for a systematic review that will evaluate the effectiveness and safety of statins and ezetimibe in people over 75 years of age.

      Steps

      Title

      1.

      Efficacy and safety of statins and ezetimibe in primary prevention of cardiovascular disease

      in the elderly: A systematic review protocol.

      Author Contributions

      2.

      JFG: conceptualization, methodology, developing the search strategy and literature search, data

      selection, extraction, statistical analysis, and writing the protocol and original draft. IIR: Support

      in the search strategy and bibliographic search, data selection and extraction, review and edit

      the protocol. NAI: Support in the search strategy and bibliographic search, review and edit the

      protocol. AEG: Support in the search strategy and bibliographic search, review and edit the

      protocol. JGP: conceptualization, methodology, develop the search strategy and search, review

      and edit the protocol and the manuscript. CL: Assist, edit and review protocol and manuscript.

      Support

      3.

      The protocol and systematic review are part of the main author's doctoral thesis. It will also

      include the results of a study on health outcomes of statin and ezetimibe deprescription strategy

      in the elderly, funded by the Institute of Health Carlos III (ISCIII) through the project PI21/01931

      and co-financed by the European Union in the Call for Action Strategy in Health (AES) 2021.

      Rationale

      4.

      Cardiovascular diseases (CVD) are the leading cause of death globally (1). The risk increases with

      age. Statins and ezetimibe are indicated for the prevention of CVD and its efficacy in secondary

      prevention (patients who have had an adverse CVD event) has been demonstrated in all age

      groups (2). However, there is controversy about its use in primary prevention (people without established CVD) in the elderly (3, 4), since the patients older than 75 years are a group of

      underrepresented population in clinical trials. This age threshold has been used in meta-analysis

      of randomized controlled trials that did not shown evidence of an effect in cardiovascular events

      in people older than 75 years without vascular disease (5–7) . The latest clinical guidelines

      published in the United States and Europe differ notably in their recommendations (8–10).

      As other medicines, statins and ezetimibe are not exempt from adverse events. These are more

      frequent in geriatric patients, since comorbidities and polypharmacy frequently coexist. These

      factors can increase the risk of drug interactions and contribute to the impairment of renal and

      hepatic function (11).

      We describe a protocol for a systematic review that will evaluate the effectiveness and safety of

      statins and ezetimibe in people over 75 years of age.

      Objective

      5.

      To assess effectiveness and safety of statins and ezetimibe in people over 75 years of age in

      primary prevention of CVD.

      Population: patients older than 75 years who do not have a history of CVD defined as ischemic

      heart disease, ischemic cerebrovascular disease, or peripheral arterial disease.

      Intervention: Treatment with statins and/or ezetimibe for the primary prevention of CVD.

      Comparator: placebo or no intervention.

      Outcomes: Death from any cause. Hospitalization. Major cardiovascular event: non-fatal

      myocardial infarction, non-fatal stroke, or cardiovascular death. For adverse effects: selfreported

      muscle symptoms, clinically confirmed muscle disorders, liver dysfunction, kidney

      failure, diabetes mellitus and eye diseases.

      Methods

      6.

      Eligibility criteria

      The studies that we will include in the review will be those carried out on the general population

      (primary care setting), over 75 years of age and who are undergoing lipid-lowering treatment

      with a statin or ezetimibe indicated for the prevention of CVD Inclusion Criteria:

      Clinical trials and analytical observational studies published since 2010 or systematic reviews

      and meta-analyses published in the last 5 years (2018-2023) (12) that report data on the

      population over the age of 75.

      Studies carried out in primary care setting, in the general population and in primary prevention

      of CVD.

      Studies whose data of outcomes of interest have been obtained or can be calculated.

      Studies with at least 1,000 patients.

      Clinical practice guidelines that issue recommendations on the use of statins or ezetimibe in

      people over 75 and in primary prevention of CVD; that are evidence-based.

      Exclusion Criteria:

      Studies in a specific subset of the population (eg, hospital outpatients, institutionalized, studies

      based on disease or diagnosis).

      Studies published exclusively as abstracts.

      Studies published in a language other than English or Spanish.

      Observational studies that select active principles.

      7.

      Information sources

      A systematic search of the literature will be conducted through the following sources: Cochrane

      Library, Pubmed, CENTRAL, Epistemonikos and EMBASE, with the date of consultation from

      January 2010 until January 2022.

      Primary studies will be identified through the ClinicalTrials.gov database, the Spanish Clinical

      Trials Registry (REEC), the EU Clinical Trials Registry, the EU post-authorization study registry

      (ENCePP), and the International Clinical Trials Registry Platform (ICTRP) of the World Health

      Organization. A search in PROSPERO will be carried out to identify completed and/or ongoing

      reviews.

      8.

      Search Strategy

      Based on the PICO elements, a preliminary search conducted on December 27th of 2022 is

      described on the Appendix 1.

      The strategy will be built with the following keywords and boolean operators for the initial

      question:

      (“Ezetimibe” AND” primary prevention [Mesh]); (“statins” AND “primary prevention” [Mesh])

      9.

      Data management

      Database search results will be imported into an Access® database. We will collate multiple

      reports of the same study.

      10.

      Selection process

      Title and abstract will be screened by two independent reviewers using the following questions:

      1. Does the title or abstract describe a study involving statins or ezetimibe?

      2. Does the title or abstract describe a study in general population or primary care (not in a

      specific subset of the population)?

      If both reviewers answer “no” for one of the questions the study will be excluded. Conflicts

      between the two reviewers will be discussed, if necessary a third reviewer will participate until

      an agreement is reached. A full manuscript screening will be performed by two reviewers. This

      screening will include following questions:

      1. Does the title or abstract describe a study involving elderly people (over 75)?

      2. Is the study conducted in primary prevention or primary and secondary prevention of CVD?

      3. Is the study an observational study (cohorts), Clinical Trials (randomized or not), systematic

      reviews or meta-analyses?

      1. Is the study written in English or Spanish?

      2. Is the study published after 2010?

      3. Is the study master size at least 1,000?

      4. Can the study provide effectiveness or safety outcomes versus placebo o no intervention in

      primary prevention of CVD?

      Studies will be excluded if answered “no” for one or more of the questions. The exclusion reason

      will be recorded at this screening level.

      We will include clinical practice guidelines that issue recommendations on the use of statins or

      ezetimibe in people over 75 and in primary prevention of CVD; that are evidence-based. For

      assessing this we will use items 7-11 in the domain 3. Rigor of Development of AGREE II

      Instrument. (13)

      11.

      Data collection process

      Data from studies will be extracted with a data extraction form into an electronic spreadsheet

      and it will be reviewed. Data extraction form will be tested on 5 studies randomly selected. Data

      extracted will include:

      1. General information: journal name, language, country, author’s name and affiliation, year of

      publication, funding information.

      1. Type of study: Observational studies (cohorts), Clinical Trials (randomized or not), systematic

      reviews or meta-analyses.

      1. Duration of the study and/or follow-up time.

      2. Limitations of the study.

      3. Population characteristics: sex and age.

      4. Intervention and comparator: Lipid-lowering agent studied: statin, ezetimibe, or both.

      5. Outcomes: type, mean differences from control, unit of results, lower/upper 95% CI, standard

      error, standard deviation, P-value, and time point of each measurement.

      For dichotomous outcomes information: number of each one, proportion, total number of each

      one, unit of results, odd ratio, relative risk, lower/ upper 95% CI, P-value, and time point of each

      measurement.

      12.

      Data items

      Outcomes and priorization

      Effectiveness and efficacy data: mortality, hospital admission, or major cardiovascular event

      (non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death).

      Adverse effects: self-reported muscle symptoms, clinically confirmed muscle disorders, liver

      dysfunction, renal insufficiency, diabetes, and eye diseases.

      Risk of bias in individual studies

      The risk of bias assessment will be performed using the RoB 2 tool for randomized trials and the

      ROBINS-I tool for non-randomised studies (14). Two reviewers will independently assess the risk

      of bias of the studies. Disagreements will be resolved by consensus, if necessary a third reviewer

      will participate until an agreement is reached.

      Studies will be classified as low risk of bias or moderate to high risk of bias.

      Data synthesis

      If the results are sufficiently homogeneous, we will do a meta-analysis.

      Heterogeneity between estimates will be tested using the I² statistic. An I² value greater than 75% will be considered as highly heterogeneous. The meta-analysis would be performed using

      a random effects model. Pooled prevalence would be calculated with a 95% confidence interval.

      Those variables identified a priori as possible sources of variation in the estimate of the effect

      will be evaluated: risk of bias and method of data collection.

      The Grading of Recommendations, Assessment, Development and Evaluations (GRADE)

      methodology will be applied to evaluate the quality of the evidence for the main outcomes (15).

      推荐阅读

      Nature Protocols
      Protocols IO
      Current Protocols
      扫码咨询